Positive Phase 1 Immune Responses in All Evaluable Ovarian and Breast Cancer Patients Advances Vaccine to Phase II Clinical Trials | 8:15 AM |
[PR Newswire] - SEATTLE, Jan. 12, 2015 /PRNewswire/ -- TapImmune Inc. (TPIV) is extremely pleased to report the completion of data analysis from all 21 evaluable patients treated in a Phase I clinical trial. In addition, the recent financing provides immediate, short term and long term access to the capital required to execute its exclusive option to license these very promising peptides and to progress its on-going clinical program into Phase II trials. In the Phase I Trial conducted and Mayo Clinic, results indicate safety and positive immune response data in Folate Receptor Alpha Vaccine for ovarian and breast cancers. Eight women with HER2-negative breast cancer, thirteen with ovarian cancer and one with fallopian tube cancer were enrolled. The data shows that the vaccine containing antigens to the Folate Receptor Alpha protein was very well tolerated and safe. Increased specific T-cell immune responses against a set of 5 naturally processed Folate Receptor Alpha Class II antigenic epitopes were detected in 21 of 21 evaluable patients.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.